Suppr超能文献

囊性纤维化中的肥胖症:来自美国囊性纤维化基金会患者登记处的患病率、趋势及相关因素数据

Obesity in Cystic fibrosis: prevalence, trends and associated factors data from the US cystic fibrosis foundation patient registry.

作者信息

Szentpetery Sylvia, Fernandez Gabriela S, Schechter Michael S, Jain Raksha, Flume Patrick A, Fink Aliza K

机构信息

Medical University of South Carolina, Charleston, SC, USA.

Cystic Fibrosis Foundation, Bethesda, MD, USA.

出版信息

J Cyst Fibros. 2022 Sep;21(5):777-783. doi: 10.1016/j.jcf.2022.03.010. Epub 2022 Apr 5.

Abstract

Strong emphasis has been placed historically on increasing weight and improving nutritional status in cystic fibrosis patients. Due to correlation between nutritional indices (e.g. BMI) and lung function, CF Nutrition Guidelines have recommended BMI percentile goals at the 50th percentile or higher. Trends in increasing BMI across CF programs suggest significantly increasing proportions of overweight and obese status in recent years. We identify that between 2000 and 2019 there has been a relative decrease in underweight status by ∼40%, simultaneously with a > 300% increase in overweight status, and >400% increase in obesity. Patient specific factors associated with higher prevalence of obesity included age ≥46, living in a zip code where the median income was < $20,000, having at least one allele with a class IV or V mutation, a ppFEV >90 prescribed ivacaftor, and not prescribed pancreatic enzymes. Program specific factors were not identified.

摘要

历史上一直非常强调增加囊性纤维化患者的体重并改善其营养状况。由于营养指标(如体重指数)与肺功能之间存在相关性,囊性纤维化营养指南建议将体重指数百分位数目标设定在第50百分位数或更高。各囊性纤维化项目中体重指数上升的趋势表明,近年来超重和肥胖状态的比例显著增加。我们发现,在2000年至2019年期间,体重过轻状态相对下降了约40%,与此同时,超重状态增加了300%以上,肥胖状态增加了400%以上。与肥胖患病率较高相关的患者个体因素包括年龄≥46岁、居住在中位数收入低于20000美元的邮政编码地区、至少有一个IV类或V类突变等位基因、规定使用依伐卡托且ppFEV>90以及未使用胰酶。未发现项目特定因素。

相似文献

1
2
Overweight and obesity in patients with cystic fibrosis: a center-based analysis.
Pediatr Pulmonol. 2015 Jan;50(1):35-41. doi: 10.1002/ppul.23033. Epub 2014 Apr 23.
6
Prevalence and factors associated with overweight and obesity in adults with cystic fibrosis: A single-center analysis.
J Cyst Fibros. 2020 Jan;19(1):139-145. doi: 10.1016/j.jcf.2019.10.004. Epub 2019 Nov 11.
7
[Italian Cystic Fibrosis Registry (ICFR). Report 2015-2016].
Epidemiol Prev. 2019 Jul-Aug;43(4S1):1-36. doi: 10.19191/EP19.4.S1.067.
9
[Italian Cystic Fibrosis Registry (ICFR). Report 2017-2018].
Epidemiol Prev. 2021 May-Jun;45(3 Suppl 1):1-37. doi: 10.19191/EP21.3.S1.050.
10
Prevalence of malnutrition and obesity among cystic fibrosis patients.
Pediatr Int. 2014 Feb;56(1):89-94. doi: 10.1111/ped.12214.

引用本文的文献

2
Glucagon-Like Peptide 1 Agonist Use in an Adult With Cystic Fibrosis-Related Diabetes and Metabolic Syndrome.
AACE Endocrinol Diabetes. 2025 Apr 11;12(2):67-70. doi: 10.1016/j.aed.2025.03.011. eCollection 2025 Jul-Aug.
4
Glucagon-like peptide-1 receptor agonists in adults with cystic fibrosis-related diabetes: Rationale and emerging evidence.
Diabetes Obes Metab. 2025 Sep;27(9):4621-4626. doi: 10.1111/dom.16516. Epub 2025 Jun 9.
5
The Aging Patient with Cystic Fibrosis.
Drugs Aging. 2025 Apr 24. doi: 10.1007/s40266-025-01207-3.
6
Cholesterol and triglyceride concentrations following 12-18 months of clinically prescribed elexacaftor-tezacaftor-ivacaftor-PROMISE sub-study.
J Clin Transl Endocrinol. 2025 Apr 2;40:100391. doi: 10.1016/j.jcte.2025.100391. eCollection 2025 Jun.
7
Challenges to Optimizing Nutrition in Children With Cystic Fibrosis.
Curr Gastroenterol Rep. 2025 Mar 7;27(1):20. doi: 10.1007/s11894-025-00969-5.
8
New era, new GOALs: cardiovascular screening and lipid management in cystic fibrosis.
Ther Adv Respir Dis. 2025 Jan-Dec;19:17534666251317200. doi: 10.1177/17534666251317200.
9
Pharmacokinetics of Omadacycline in Adults with Cystic Fibrosis.
Clin Pharmacokinet. 2024 Dec;63(12):1701-1709. doi: 10.1007/s40262-024-01440-w. Epub 2024 Nov 24.

本文引用的文献

1
The Impact of Highly Effective CFTR Modulators on Growth and Nutrition Status.
Nutrients. 2021 Aug 24;13(9):2907. doi: 10.3390/nu13092907.
2
Academy of Nutrition and Dietetics: 2020 Cystic Fibrosis Evidence Analysis Center Evidence-Based Nutrition Practice Guideline.
J Acad Nutr Diet. 2021 Aug;121(8):1591-1636.e3. doi: 10.1016/j.jand.2020.03.015. Epub 2020 Jun 19.
5
Nutritional excess in cystic fibrosis: the skinny on obesity.
J Cyst Fibros. 2020 Jan;19(1):3-5. doi: 10.1016/j.jcf.2019.12.002. Epub 2019 Dec 13.
6
Prevalence and factors associated with overweight and obesity in adults with cystic fibrosis: A single-center analysis.
J Cyst Fibros. 2020 Jan;19(1):139-145. doi: 10.1016/j.jcf.2019.10.004. Epub 2019 Nov 11.
7
Energy balance and obesity in individuals with cystic fibrosis.
J Cyst Fibros. 2019 Oct;18 Suppl 2:S38-S47. doi: 10.1016/j.jcf.2019.08.015.
8
The Cystic Fibrosis Foundation Patient Registry. Design and Methods of a National Observational Disease Registry.
Ann Am Thorac Soc. 2016 Jul;13(7):1173-9. doi: 10.1513/AnnalsATS.201511-781OC.
10
Overweight and obesity in deltaF508 homozygous cystic fibrosis.
J Pediatr. 2005 Sep;147(3):402-4. doi: 10.1016/j.jpeds.2005.06.003.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验